{
    "name": "omalizumab",
    "comment": "Rx",
    "other_names": [
        "Xolair"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Anti-asthmatics"
    ],
    "source": "https://reference.medscape.com/drug/xolair-omalizumab-343444",
    "pregnancy": {
        "common": [
            "Exposure during pregnancy showed no increase in rate of major birth defects or miscarriage;",
            "Increased rate of low birth weight among registry infants compared to infants in the other cohorts reported, despite average gestational age at birth; however, women taking the drug during pregnancy also had more severe asthma, which makes it difficult to determine whether ow birth weight is due to drug or disease severity",
            "Monoclonal antibodies, such as omalizumab, are transported across placenta in a linear fashion as pregnancy progresses; potential effects on fetus are likely to be greater during second and third trimesters of pregnancy",
            "In women with poorly or moderately controlled asthma, evidence demonstrates that there is increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate; level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control ",
            "Human IgG antibodies are known to cross placental barrier; therefore, drug may be transmitted from mother to developing fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Majority of infants (80.9%, 186/230) in pregnancy exposure registry were breastfed; events categorized as “infections and infestations” were not significantly increased in infants who were exposed through breastfeeding compared with infants who were not breastfed, or infants who were breastfed without exposure"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis",
                    "description": [
                        "Anaphylaxis (eg, bronchospasm, hypotension, syncope, urticaria, angioedema of throat or tongue) reported ",
                        "Anaphylaxis has occurred as early as after first dose, but also has occurred beyond 1 year after beginning regularly administered treatment",
                        "Initiate therapy in a healthcare setting and closely observe patients for an appropriate period after administration ",
                        "Be prepared to manage anaphylaxis that can be life-threatening",
                        "Inform patients of the signs and symptoms of anaphylaxis and instruct to seek immediate medical care should symptoms occur",
                        "Base selection for self-administration on criteria to mitigate risk from anaphylaxis "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Severe hypersensitivity reaction to omalizumab or any of its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of anaphylaxis may occur up to 24 hr after any dose, even if no reaction to the first dose; advise patients to carry emergency self-treatment; discontinue if severe hypersensitivity reaction occurs ",
                "Once therapy has been established, administration by prefilled syringe outside of a healthcare setting by a patient or a caregiver may be appropriate for selected patients; patient selection, determined by healthcare provider in consultation with patient, should take into account the pattern of anaphylaxis events seen in premarketing clinical trials and postmarketing spontaneous reports, as well as individual patient risk factors (eg, prior history of anaphylaxis), ability to recognize signs and symptoms of anaphylaxis, and ability to perform subcutaneous injections with prefilled syringe with proper technique according to prescribed dosing regimen and instructions for use",
                "Do not discontinue systemic or inhaled corticosteroids abruptly upon initiating omalizumab; decrease corticosteroids gradually over weeks/months; use with corticosteroids has not been evaluated in patients with CIU",
                "Arthritis/arthralgia, rash, fever, and lymphadenopathy reported",
                "Malignant neoplasms were observed; malignancy rate was 0.5% compared to 0.2% of controls in clinical trials; a 5-year study found difference in the rates of cancer between omalizumab-treated patients and those who were not treated, but due to limitations of the study, increased cancer risk cannot be ruled out ",
                "Monitor patients at high risk for geohelminth infection while taking omalizumab",
                "Monitor for eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy, especially upon reduction of oral corticosteroids",
                "Not shown to alleviate asthma exacerbations acutely; not for use in acute bronchospasm or status asthmaticus; patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with therapy",
                "Elevated serum total IgE levels may persist for up to 1 yr following discontinuation; do not use serum total IgE levels obtained <1 year following discontinuation to reassess dosing regimen for asthma or nasal polyps "
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "45"
        },
        {
            "name": "Headache",
            "percent": "12"
        },
        {
            "name": "Arthralgia",
            "percent": "8"
        },
        {
            "name": "Pain",
            "percent": "7"
        },
        {
            "name": "Leg pain",
            "percent": "4"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Earache",
            "percent": "2"
        },
        {
            "name": "Pruritus",
            "percent": "2"
        },
        {
            "name": "Dermatitis",
            "percent": "2"
        },
        {
            "name": "Arm pain",
            "percent": "2"
        },
        {
            "name": "Fracture",
            "percent": "2"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "9.1"
        },
        {
            "name": "Arthralgia",
            "percent": "2.9"
        },
        {
            "name": "Viral upper respiratory tract infection",
            "percent": "2.3"
        },
        {
            "name": "Nausea",
            "percent": "1.1"
        },
        {
            "name": "Cough",
            "percent": "1.1"
        },
        {
            "name": "Sinusitis",
            "percent": "1.1"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "1.1"
        },
        {
            "name": "Headache",
            "percent": "8.1"
        },
        {
            "name": "Injection site reactions",
            "percent": "5.2"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3"
        },
        {
            "name": "Arthralgia",
            "percent": "3"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        }
    ]
}